EUVIMEDEUVIMED entdecken
Crossref

Broad-Spectrum Activity of Peptide-Linked Amikacin Conjugates in Synergy with Polymyxin B against Extensively Drug-Resistant and Pandrug-Resistant Bacteria

Sandra Story, Anindra Sharma, Krishnagopal Maiti, Dev P Arya iD

ACS Infectious Diseases · 2026

DOI: 10.1021/acsinfecdis.5c00798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2026. Verfasst von Sandra Story und 3 weiteren Autor:innen. Beteiligte Einrichtung: NUBAD, LLC, Greenville, South Carolina 29605, United States. Hauptthemen laut MEDLINE: Amikacin, Anti-Bacterial Agents, Polymyxin B, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 76 Literaturangaben. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Global dissemination of genes conferring carbapenem and aminoglycoside resistance has put Klebsiella at the top of the World Health Organization's list of critical priority pathogens. The burgeoning arsenal of aminoglycoside modifying enzymes (AMEs) and 16S rRNA methyltransferases (RMTases) threatens to render aminoglycosides ineffective. Drug combination therapy such as polymyxin and aminoglycoside amikacin has been indicated for drug-resistant Klebsiella infections. The goal of this study was to chemically synthesize and study the antibacterial activity for a novel peptide-linked amikacin library combined with polymyxin. Amikacin derivatives with amino acids containing a positive charge, containing sulfur or with aromatic side chains, were synergistic with polymyxin B against amikacin and pandrug-resistant bacteria. Of 31 Klebsiella pneumoniae strains screened with amikacin peptides containing tryptophan and cysteine with polymyxin, synergy was observed in 77% of strains, including those carrying multiple AME and RMTases. P-AMK compounds behave similarly to AMK, with or without PMB, in killing mammalian cells, but are much more synergistic (as compared to AMK) with PMB in killing drug-resistant bacterial cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmikacinAnti-Bacterial AgentsPolymyxin BDrug Resistance, Multiple, BacterialKlebsiella pneumoniaePeptidesDrug SynergismMicrobial Sensitivity TestsHumans

Stichwörter der Autor:innen

amino acidsaminoglycosidesdrug-resistant bacteriapeptide-amikacin conjugatespolymyxinsynergy

Substanzen

AmikacinAnti-Bacterial AgentsPolymyxin BPeptides

Autor:innen und Institutionen

  • NUBAD, LLC, Greenville, South Carolina 29605, United States.
  • Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.

ORCID-Profile: Dev P Arya

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Story, S., Sharma, A., Maiti, K., & Arya, D. P. (2026). Broad-Spectrum Activity of Peptide-Linked Amikacin Conjugates in Synergy with Polymyxin B against Extensively Drug-Resistant and Pandrug-Resistant Bacteria. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.5c00798

Vancouver

Story S, Sharma A, Maiti K, Arya DP. Broad-Spectrum Activity of Peptide-Linked Amikacin Conjugates in Synergy with Polymyxin B against Extensively Drug-Resistant and Pandrug-Resistant Bacteria. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.5c00798

BibTeX
@article{Story2026,
  author = {Story, Sandra and Sharma, Anindra and Maiti, Krishnagopal and Arya, Dev P},
  title = {Broad-Spectrum Activity of Peptide-Linked Amikacin Conjugates in Synergy with Polymyxin B against Extensively Drug-Resistant and Pandrug-Resistant Bacteria},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.5c00798}
}
Kostenlos starten →